NuVasive Company Profile (NASDAQ:NUVA)

About NuVasive

NuVasive logoNuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company's spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company's biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: NUVA
  • CUSIP: 67070410
Key Metrics:
  • Previous Close: $73.56
  • 50 Day Moving Average: $70.93
  • 200 Day Moving Average: $66.26
  • 52-Week Range: $37.95 - $75.10
  • Trailing P/E Ratio: 106.61
  • Foreward P/E Ratio: 29.54
  • P/E Growth: 2.44
  • Market Cap: $3.72B
  • Outstanding Shares: 50,599,000
  • Beta: 0.86
  • Net Margins: 3.29%
  • Return on Equity: 12.26%
  • Return on Assets: 5.35%
  • Debt-to-Equity Ratio: 0.81%
  • Current Ratio: 2.37%
  • Quick Ratio: 1.51%
Additional Links:
Companies Related to NuVasive:

Analyst Ratings

Consensus Ratings for NuVasive (NASDAQ:NUVA) (?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $71.70 (2.53% downside)

Analysts' Ratings History for NuVasive (NASDAQ:NUVA)
DateFirmActionRatingPrice TargetDetails
2/21/2017Canaccord GenuityReiterated RatingBuy$82.00View Rating Details
2/16/2017Barclays PLCReiterated RatingOverweight$76.00 -> $80.00View Rating Details
2/16/2017Jefferies Group LLCReiterated RatingBuy$79.00 -> $84.00View Rating Details
2/10/2017Needham & Company LLCReiterated RatingHoldView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00View Rating Details
9/1/2016Piper Jaffray CompaniesReiterated RatingOverweight$70.00View Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 -> $70.00View Rating Details
7/13/2016J P Morgan Chase & CoUpgradeNeutral -> Overweight$55.00 -> $74.00View Rating Details
6/7/2016Morgan StanleyReiterated RatingHold$57.00View Rating Details
5/10/2016Leerink SwannReiterated RatingBuy$65.00View Rating Details
4/27/2016Cowen and CompanyReiterated RatingBuy$52.00 -> $63.00View Rating Details
12/11/2015Bank of America CorpUpgradeUnderperform -> Neutral$56.00View Rating Details
10/6/2015BMO Capital MarketsUpgradeMarket Perform -> Outperform$52.00 -> $64.00View Rating Details
10/5/2015Royal Bank Of CanadaReiterated RatingOutperform$58.00View Rating Details
7/29/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$48.00 -> $68.00View Rating Details
6/3/2015Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$52.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for NuVasive (NASDAQ:NUVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.25$0.19$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.23$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NuVasive (NASDAQ:NUVA)
Current Year EPS Consensus Estimate: $2.02 EPS
Next Year EPS Consensus Estimate: $2.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.25$0.32$0.29
Q2 20166$0.33$0.39$0.37
Q3 20163$0.39$0.40$0.40
Q4 20163$0.50$0.52$0.51
Q1 20173$0.37$0.39$0.38
Q2 20173$0.48$0.50$0.49
Q3 20173$0.51$0.55$0.54
Q4 20173$0.62$0.65$0.64
Q2 20181$0.61$0.61$0.61
Q3 20181$0.60$0.60$0.60
(Data provided by Zacks Investment Research)


Dividend History for NuVasive (NASDAQ:NUVA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NuVasive (NASDAQ:NUVA)
Insider Ownership Percentage: 4.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.38View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.69View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.12View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.00View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.23View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.00View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.08View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.00View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.84View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.24View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.00View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.00View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.00View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.72View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.00View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.00View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.00View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.00View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.93View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.00View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.50View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.59View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.00View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.00View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.95View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.68View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for NuVasive (NASDAQ:NUVA)
News IconNuVasive Posts 25.9% Fourth Quarter Sales Increase (NASDAQ:NUVA) - February 22 at 7:01 PM logoCouncil talks taking back Beale Street, EDGE authority (NASDAQ:NUVA) - February 22 at 8:57 AM
News IconAnalysts Peer Into Their Crystal Balls For NuVasive, Inc. (NASDAQ:NUVA): Where Is It headed? - Winfield Review (NASDAQ:NUVA) - February 21 at 5:57 PM
News IconTed Evanoff: Tax break sounds excessive - The Commercial Appeal (NASDAQ:NUVA) - February 18 at 11:52 AM logoNuVasive : gets $9 million PILOT for 15 jobs, $116M investment (NASDAQ:NUVA) - February 17 at 4:35 PM
News IconCompany: Fiber optics growing in region (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconCompany: Fiber optics growing in region (NASDAQ:NUVA) - February 16 at 6:29 PM logoNuVasive : Manufacturer secures rapid growth in medical devices (NASDAQ:NUVA) - February 16 at 6:29 PM logoNuVasive : Manufacturer secures rapid growth in medical devices (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconNuVasive wins $9m tax break for Tennessee distro hub (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconNuVasive wins $9m tax break for Tennessee distro hub (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconNuVasive Receives 11-Year PILOT, Will Invest $116 Million (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconNuVasive Receives 11-Year PILOT, Will Invest $116 Million (NASDAQ:NUVA) - February 16 at 6:29 PM logoNuVasive, Inc. :NUVA-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017 (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconWhy Analysts put forward these two stocks: NuVasive, Inc. (NUVA), Healthcare Trust of America, Inc. (HTA) - The USA Commerce (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconPulling Back The Curtain on NuVasive, Inc. (NASDAQ:NUVA): Analysts & Wall Street Chime In - Winfield Review (NASDAQ:NUVA) - February 16 at 6:29 PM logoNUVASIVE INC Financials (NASDAQ:NUVA) - February 16 at 6:29 PM
News IconPeeling Back The Layers on NuVasive, Inc. (NASDAQ:NUVA): Analysts & Street Weigh In - Winfield Review (NASDAQ:NUVA) - February 14 at 10:06 PM logoMaker of spine surgery aids calls for repeal of medical device tax (NASDAQ:NUVA) - February 13 at 8:07 PM
News IconNuVasive Posts Record Revenue of $962.1 Million for 2016 (NASDAQ:NUVA) - February 13 at 8:07 PM logoNuVasive, Inc. :NUVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 13, 2017 (NASDAQ:NUVA) - February 13 at 9:36 AM logoNuVasive (NUVA) PT Raised to $84 at Jefferies Following Results (NASDAQ:NUVA) - February 11 at 12:56 AM
News IconNuVasive posts Street-beating Q4, FY2016 (NASDAQ:NUVA) - February 10 at 7:51 PM logoEdited Transcript of NUVA earnings conference call or presentation 9-Feb-17 9:30pm GMT (NASDAQ:NUVA) - February 10 at 7:51 PM logoNuVasive (NUVA) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:NUVA) - February 10 at 1:00 AM
News IconNuVasive Inc (NUVA): What does the future look like? (NASDAQ:NUVA) - February 9 at 7:59 PM logoNuVasive Provides Updated Financial Guidance For 2017 - Quick Facts (NASDAQ:NUVA) - February 9 at 7:59 PM logoNuVasive, Inc. Reports 53% Gain In Q4 Earnings (NASDAQ:NUVA) - February 9 at 7:59 PM logoNuVasive, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:NUVA) - February 9 at 7:59 PM logoQ4 2016 NuVasive Inc Earnings Release - After Market Close (NASDAQ:NUVA) - February 9 at 7:59 PM logoNuVasive Reports Fourth Quarter And Full Year 2016 Financial Results (NASDAQ:NUVA) - February 9 at 7:59 PM logoNUVASIVE INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial S (NASDAQ:NUVA) - February 9 at 7:59 PM logoNuVasive tops Street 4Q forecasts (NASDAQ:NUVA) - February 9 at 7:59 PM logoNuVasive Builds Momentum Going Into 2017 (NASDAQ:NUVA) - February 9 at 7:59 PM logoManufacturer hiring 200+ at Dayton-area facility (NASDAQ:NUVA) - February 9 at 5:54 AM
News IconInside the Numbers for NuVasive, Inc. (NASDAQ:NUVA) - Baldwin Journal (NASDAQ:NUVA) - February 8 at 7:51 PM
News IconU.S. Orthopedic Devices Market Benefits from Demand for Several Types of Orthopedic Surgeries (NASDAQ:NUVA) - February 8 at 2:30 AM logoWhy NuVasive (NUVA) Might Surprise This Earnings Season - Nasdaq (NASDAQ:NUVA) - February 7 at 9:28 PM logoWhy NuVasive (NUVA) Might Surprise This Earnings Season (NASDAQ:NUVA) - February 7 at 9:20 AM logoNuVasive To Present At Leerink Partners 6th Annual Global Healthcare Conference 2017 (NASDAQ:NUVA) - February 6 at 9:29 AM
News IconDegenerative Disc Disease Treatment Market: Global Industry Analysis & Forecast upto 2024 (NASDAQ:NUVA) - February 3 at 7:43 PM logoFirst Week of September 15th Options Trading For Nuvasive (NUVA) (NASDAQ:NUVA) - February 3 at 7:43 PM logoInsiders Buy the Holdings of XHE ETF (NASDAQ:NUVA) - February 2 at 7:50 PM logoForm 4 NUVASIVE INC For: Jan 28 Filed by: Miles Patrick (NASDAQ:NUVA) - February 1 at 1:00 AM
News IconHood River Capital Management LLC Raised Stake in Nuvasive INC (NUVA) by $7.58 Million (NASDAQ:NUVA) - January 31 at 7:56 PM
News IconTrading Insight: Taking a Look at Levels for NuVasive Inc. (NUVA) - Springdale Times (NASDAQ:NUVA) - January 30 at 7:35 PM
News IconSell-side Taking Aim at Shares of NuVasive, Inc. (NASDAQ:NUVA) - Aiken Advocate (NASDAQ:NUVA) - January 30 at 7:35 PM logoDayton region enters 2017 with strong momentum (NASDAQ:NUVA) - January 30 at 8:53 AM
News IconEarnings in Full Force, Analysts Take Aim at NuVasive, Inc. (NASDAQ:NUVA) - Wall Street Beacon (NASDAQ:NUVA) - January 27 at 4:46 AM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on NuVasive, Inc. (NASDAQ:NUVA) - Wall Street Beacon (NASDAQ:NUVA) - January 27 at 4:46 AM


What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Where is NuVasive's stock going? Where will NuVasive's stock price be in 2017?

11 analysts have issued 1-year price objectives for NuVasive's shares. Their predictions range from $57.00 to $84.00. On average, they expect NuVasive's stock price to reach $71.70 in the next twelve months.

When will NuVasive announce their earnings?

NuVasive is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.

What are analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:

  • According to Zacks Investment Research, "NuVasive witnessed robust share price movement as compared to the Zacks categorised Medical Product industry in the past one month. However a disappointing estimate revision trend indicates looming concerns ahead. The company posted disappointing third-quarter results, with both earnings and revenues missing the Zacks Consensus Estimate. However, on a positive note, the company saw double-digit growth in Spinal Hardware and Surgical Support businesses. The company presently is rapidly developing technologies and services for spine surgery. Further, NuVasive recently included NSO and Biotronic NeuroNetwork which is expected to strengthen its foothold in the growing spine market. On the flip side pricing and margin pressures, reimbursement issues and competitive landscape are major downsides." (12/28/2016)

  • Leerink Swann analysts commented, "We view NUVA’s acquisition of its Brazilian distributor as a positive move, which increases our confidence in NUVA’s ability to achieve OUS growth targets. Yesterday, the company announced that it has entered into a definitive agreement to acquire Mega Surgical, the exclusive distributor of NUVA’s products in Brazil. Deal terms were not disclosed, as (according to mgmt.) it’s immaterial. The transaction is expected to close during 1Q16. Recall, Brazil has been a trouble spot for a number of ortho players, including NUVA over the past few quarters. For NUVA, the problem has been a bit more pronounced on the cash collection front where management indicated that, despite solid end-market trends (i.e., surgeries still getting done) it had been unable to collect payments from the region which the company indicated (in our follow-up w/ mgmt.) would have amounted to ~$1M in sales during 4Q15. Using the 4Q15 $1M commentary as an approximate run-rate, we estimate NUVA’s Brazil distributor was accounting for somewhere in the neighborhood of ~$3-4M worth of business annually (end-market generated, not necessarily cash collected)." (3/17/2016)

Who owns NuVasive stock?

NuVasive's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Champlain Investment Partners LLC (3.71%), State Street Corp (3.18%), Dimensional Fund Advisors LP (2.15%), Alyeska Investment Group L.P. (1.78%), Viking Global Investors LP (1.38%) and Thrivent Financial for Lutherans (1.18%). Company insiders that own NuVasive stock include Alexis V Lukianov, Gregory T Lucier, Jack R Blair, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles, Quentin S Blackford and Russell Powers.

Who sold NuVasive stock? Who is selling NuVasive stock?

NuVasive's stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Federated Investors Inc. PA, State Street Corp, Castleark Management LLC, Cipher Capital LP, Turner Investments LLC, Nicholas Co. Inc. WI and Ramsey Quantitative Systems. Company insiders that have sold NuVasive stock in the last year include Jason Hannon, Lesley H Howe and Matthew Link.

Who bought NuVasive stock? Who is buying NuVasive stock?

NuVasive's stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Hodges Capital Management Inc., Alyeska Investment Group L.P., Champlain Investment Partners LLC, Russell Investments Group Ltd., Guggenheim Capital LLC, Seven Eight Capital LP and Highland Capital Management LP. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran and Patrick Miles.

How do I buy NuVasive stock?

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NuVasive stock cost?

One share of NuVasive stock can currently be purchased for approximately $73.56.

NuVasive (NASDAQ:NUVA) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Earnings History Chart

Earnings by Quarter for NuVasive (NASDAQ:NUVA)

Dividend History Chart

Dividend Payments by Quarter for NuVasive (NASDAQ:NUVA)

Last Updated on 2/23/2017 by Staff